title: IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's Lymphoma Ascites tumor model.
abstract: ETB receptor agonist, IRL-1620 (or SPI-1620) presently in US Phase 1 clinical trial, has been demonstrated to selectively and transiently increase tumor blood flow. The present study was conducted to determine the effect of IRL-1620 on radiation therapy in tumor bearing mice inoculated with Dalton's Lymphoma Ascites cells. Tumors were allowed to grow for 30 days to a size of 1.10-1.29 cm3 before starting the treatment. The animals with or without IRL-1620 treatment were exposed to radiation (4 Gy/dose) on every alternate day for a total of 5 doses. Tumor volume was determined twice every week till the end of study. Radiation alone did not affect the tumor volume; however, animals treated with IRL-1620 followed by radiation produced a significant (64%) reduction in tumor volume. Survival of mice improved from 0/10 at 56 days after tumor inoculation in vehicle plus radiation group to 6/10 at 70 days in IRL-1620 (9 nmol/kg) plus radiation group. It is concluded that IRL-1620 improves the efficacy of radiation treatment in tumor bearing mice. (These findings have been earlier presented as an abstract ).
authors.affiliation: Department of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, USA. AGULAT@midwestern.edu
authors.forename: A
authors.initials: A
authors.lastname: Gulati
authors.forename: E S
authors.initials: ES
authors.lastname: Sunila
authors.forename: G
authors.initials: G
authors.lastname: Kuttan
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D016232:Endothelins; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D051379:Mice; D010446:Peptide Fragments; D044023:Receptor, Endothelin B / Q000819:agonists*; D047368:Tumor Burden
chemical_list: D016232:Endothelins; D010446:Peptide Fragments; D044023:Receptor, Endothelin B; C074308:sovateltide